Across TCGA pan-cancer cohorts, RNU6-1025P RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RNU6-1025P’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RNU6-1025P RNA is repressed in tumor relative to normal tissue. In most cancer types RNU6-1025P is over-expressed in tumor, although a few such as BRCA and THCA show the opposite, repressed pattern.

BRCA, STAD, and CHOL are the cancer types where RNU6-1025P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-1025P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	−0.172	.028	2	view →
STAD	All	III,IV	+0.983	.020	1	view →
CHOL	All	All	+0.410	.032	1	view →
THCA	All	II,III,IV	−0.153	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RNU6-1025P RNA expression & survival · all RNU6-1025P data types